

23rd November, 2023

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Clarification on news item appearing in in www.cnbctv18.com

This is in reference to clarification sought from the Company by the stock exchanges on news item appeared on www.cnbctv18.com dated 23rd November, 2023 captioned "Cipla shares top Nifty 50 losers after biggest fall in nine months; CNBC-TV18 accesses Pithampur warning letter".

In this regard, we submit as under:

- We confirm that the Company had received Warning Letter on 18th November, 2023, which was duly disclosed to the stock exchanges in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, on 18th November, 2023. Sequence of events is as follows:

Date	Sequence of events
Saturday, 18 th November, 2023	Receipt of warning letter from United States Food and Drugs Administration (USFDA) dated 17 th November, 2023
Saturday, 18 th November, 2023	Intimation to stock exchanges

- The news article covers the same event and there is no new development requiring additional disclosure by the Company.
- The Warning Letter received from US FDA was in continuation of observations received in Form 483 on 17th February, 2023 and inspection classification of the said facility as Official Action Indicated ("OAI") received on 5th August, 2023. Both these communications from USFDA were intimated to the stock exchanges within 24 hours of receipt. As informed in our intimation dated 5th August, 2023, we once again confirm that we do not see material risk to our existing commercial product portfolio. The Company is in

the process of executing de-risking plan for its new products and simultaneously addressing the observations expeditiously.

We also submit that we uphold quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards.

The Company is in process of submitting requisite response to the Warning Letter within the stipulated timelines and shall work closely with the USFDA to address the concerns.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode